SOUTH SAN FRANCISCO, CA--(Marketwire - February 23, 2008) - Theravance, Inc. (NASDAQ: THRX) announces that the U.S. Food and Drug Administration has cancelled the Anti-Infective Drugs Advisory Committee meeting scheduled for February 27, 2008 to discuss telavancin, proposed for the treatment of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
